$ARQT News

UPDATE: Arcutis Highlights New Expert Guidance For Diagnosing And Managing Genital Psoriasis Across All Age Groups

Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary

Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target

Arcutis Biotherapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript

Arcutis Biotherapeutics Q1 Earnings Call Highlights

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates

Arcutis Biotherapeutics (NASDAQ:ARQT) Beats Q1 Revenue Estimates but Posts Wider-Than-Expected Loss; Shares Slide

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $105.398M Beat $101.261M Estimate

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

Arcutis Biotherapeutics Announces Submission Of sNDA To FDA Seeking To Expand Indication For ZORYVE Cream 0.05% To Include Topical Treatment Of Atopic Dermatitis In Infants Down To 3 Months

A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves

How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target

Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

Arcutis Biotherapeutics Announces ZORYVE Cream Receives Strong Recommendation, With High Certainty Of Clinical Evidence, In AAD Clinical Practice Guidelines For Management Of Pediatric Atopic Dermatitis

Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants

Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026